{"ContentType":"textComponent","Id":"bf4556b1-62a7-4523-ac29-9363fce7468d","Properties":{"text":{"Markup":"

The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of EUR 500,000 (approximately 4M DKK) plus access to labs and offices at BII in Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII’s Venture House program.

The new companies BII has accepted into the Venture Lab program are:

Human Health:

PanTarg are cracking the toughest tumors with a dual-attack cancer therapy.

Monix is on a mission to develop the world’s first wearable biosensor for continuous real-time monitoring of key female hormones.

Imprint Medicine is developing novel epigenetic editors for one-time treatment of CNS disorders.

INIA Biosciences is revolutionizing the treatment of inflammation.

CARE-DNA works to improve the survival rate of the world’s deadliest cancers through early detection.

Planetary Health:

June Bio helps the two billion people suffering from mucosal damage by unlocking the power of mucin proteins.

Sagava decarbonizes maritime shipping with sustainable biofuel from waste.

Pura Futura turns renewable power into competitive e-fuel by boosting the yield at existing biogas plants.

Societal Resilience:

QVersion is unlocking new colours to fly beyond the limits of on-chips sensing.

Celare Quantum Communications uses quantum technology to secure the most sensitive data – today and in the quantum future.

","Blocks":[]}}}